Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
I124963-1g | 1g | In stock | $9.90 | |
I124963-5g | 5g | In stock | $22.90 | |
I124963-25g | 25g | In stock | $77.90 | |
I124963-100g | 100g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $248.90 |
Synonyms | Imatinib|152459-95-5|STI571|Imatinib (STI571)|Imatinib free base|Glamox|N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide|Cgp 57148|STI 571|CCRIS 9076|UNII-BKJ8M8G5HI|BKJ8M8G5HI|Imatinib (INN)|NSC-743 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | IC50 Value: 100 nM (PDGFR) ; 100 nM (c-Kit) Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of ABL proto-oncogene 1; non-receptor tyrosine kinase;Inhibitor of discoidin domain receptor tyrosine kinase 1;Inhibitor of discoidin domain receptor tyrosine kinase 2 |
Note | 250mg卖完停产,不再备货 |
Product Description | Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
---|---|
INCHI | InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) |
InChi Key | KTUFNOKKBVMGRW-UHFFFAOYSA-N |
Canonical SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
Isomeric SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
PubChem CID | 5291 |
Molecular Weight | 493.6 |
CAS Registry No. | 152459-95-5 |
---|---|
DrugBank Ligand | DB00619 |
Wikipedia | Imatinib |
DiscoveRx TREEspot | Imatinib| |
PubChem CID | 5291 |
ChEBI | CHEBI:45783 |
ChEMBL Ligand | CHEMBL941 |
RCSB PDB Ligand | STI |
PEP | imatinib |
Reactome Reaction | R-HSA-9669859, R-HSA-9674397, R-HSA-9669854, R-HSA-9669900, R-HSA-9674430, R-HSA-9674095 |
Reactome Drug | R-ALL-9659761 |
DrugCentral Ligand | 1423 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
D2423384 | Certificate of Analysis | Apr 10, 2024 | I124963 |
D2423385 | Certificate of Analysis | Apr 10, 2024 | I124963 |
D2423386 | Certificate of Analysis | Apr 10, 2024 | I124963 |
D2423387 | Certificate of Analysis | Apr 10, 2024 | I124963 |
D2423388 | Certificate of Analysis | Apr 10, 2024 | I124963 |
D2407362 | Certificate of Analysis | Mar 16, 2024 | I124963 |
D2120025 | Certificate of Analysis | Feb 09, 2023 | I124963 |
L2208873 | Certificate of Analysis | Nov 22, 2022 | I124963 |
L2208881 | Certificate of Analysis | Nov 22, 2022 | I124963 |
L2208882 | Certificate of Analysis | Nov 22, 2022 | I124963 |
L2209006 | Certificate of Analysis | Nov 22, 2022 | I124963 |
D1628077 | Certificate of Analysis | Jan 19, 2022 | I124963 |
Solubility | DMSO 3 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
---|---|
Sensitivity | Heat & air sensitive |
Refractive Index | 1.67 |
Boil Point(°C) | 715.75° C |
Melt Point(°C) | 211-213°C |
Pictogram(s) | GHS08 |
---|---|
Signal | Danger |
Hazard Statements | H341:Suspected of causing genetic defects H351:Suspected of causing cancer H360:May damage fertility or the unborn child H361:Suspected of damaging fertility or the unborn child H362:May cause harm to breast-fed children |
Precautionary Statements | P280:Wear protective gloves/protective clothing/eye protection/face protection. P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P260:Do not breathe dust/fume/gas/mist/vapors/spray. P281:Use personal protective equipment as required. P270:Do not eat, drink or smoke when using this product. P263:Avoid contact during pregnancy/while nursing. P203:Obtain, read and follow all safety instructions before use. P318:if exposed or concerned, get medical advice. |
Merck Index | 4902 |
1. Takeuchi K, Koike K, Kamijo T, Ishida S, Nakazawa Y, Kurokawa Y, Sakashita K, Kinoshita T, Matsuzawa S, Shiohara M et al.. (2003) STI571 inhibits growth and adhesion of human mast cells in culture.. J Leukoc Biol, 74 (6): (1026-34). [PMID:12960256] |
2. Rhee CK, Kim JW, Park CK, Kim JS, Kang JY, Kim SJ, Kim SC, Kwon SS, Kim YK, Park SH et al.. (2011) Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma.. Int Arch Allergy Immunol, 155 (3): (243-51). [PMID:21293142] |
3. Ustun C, DeRemer DL, Akin C. (2011) Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.. Leuk Res, 35 (9): (1143-52). [PMID:21641642] |
4. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. (2016) Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.. J Virol, 90 (19): (8924-33). [PMID:27466418] |
5. Sisk JM, Frieman MB, Machamer CE. (2018) Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.. J Gen Virol, 99 (5): (619-630). [PMID:29557770] |